NxStage Medical (NASDAQ:NXTM) has received an average broker rating score of 2.00 (Buy) from the six analysts that provide coverage for the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong sell rating, one has issued a hold rating and four have issued a strong buy rating on the company.

Analysts have set a 12-month consensus target price of $21.00 for the company and are expecting that the company will post ($0.10) EPS for the current quarter, according to Zacks. Zacks has also assigned NxStage Medical an industry rank of 112 out of 265 based on the ratings given to its competitors.

In other NxStage Medical news, President Joseph E. Turk, Jr. sold 2,000 shares of NxStage Medical stock in a transaction dated Tuesday, June 23rd. The shares were sold at an average price of $15.36, for a total transaction of $30,720.00. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Jeffrey H. Burbank sold 20,000 shares of the company’s stock in a transaction dated Thursday, June 18th. The stock was sold at an average price of $15.56, for a total transaction of $311,200.00. The disclosure for this sale can be found here.

Separately, analysts at Zacks reiterated a “hold” rating on shares of NxStage Medical in a research note on Thursday, June 4th.

NxStage Medical (NASDAQ:NXTM) opened at 14.285 on Wednesday. NxStage Medical has a one year low of $11.50 and a one year high of $19.63. The stock’s 50-day moving average is $15.85 and its 200-day moving average is $17.36. The company’s market cap is $903.35 million.

NxStage Medical (NASDAQ:NXTM) last posted its quarterly earnings results on Wednesday, May 6th. The medical device company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.02. The company had revenue of $79.50 million for the quarter, compared to the consensus estimate of $77.92 million. During the same quarter in the previous year, the company posted ($0.09) earnings per share. The company’s revenue for the quarter was up 10.1% on a year-over-year basis. Analysts expect that NxStage Medical will post $-0.360 EPS for the current fiscal year.

NxStage Medical, Inc. (NASDAQ:NXTM)is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Company’s primary product is the NxStage System One (System One). It also sells needles and blood tubing sets primarily to dialysis clinics for the treatment of end-stage renal disease (ESRD). The Company operates in two segments: System One and In-Center. It distributes its products in three markets: home, critical care and in-center. In the System One segment it sells and rents the System One, PureFlow SL equipment and disposable products in the home and critical care markets. In the In-Center segment, it sells of blood tubing sets and needles for hemodialysis at dialysis centers and needles for apheresis. The Company’s products include the NxStage System One, Streamline Blood Tubing Sets and AV Fistula and Apheresis Needles.

To get a free copy of the research report on NxStage Medical (NXTM), click here. For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.

...